Radiation Oncology

Editor notes

Radiation Oncology

Corresponding author: Niharika M, Department of Bioinformatics, School of Biosciences and Technology, VIT University, Vellore, Tamil Nadu, India

Radiation oncology is a treatment procedure that involves the use of radiation beams in controlled manner to treat cancer and other symptoms caused by cancer. Radiation therapy or radiotherapy is the term used to describe the actual treatment delivered by the radiation oncologists.

The scope of the JJ of Radiation Oncology embraces all the areas of radiation oncology that impacts on the treatment of cancer using radiation and it also publishes articles on the complete study of cancer that includes prevention, diagnosis, therapy, prognosis aspects and ethical issues surrounding cancer care at cellular and molecular levels along with the study of malignances and tumors.

The JJ of Radiation Oncology volume3 issue 3 published articles discussing on Carbon ions Versus γ-Irradiation: The Telomeric Effect in Cancer Cells [1], Radiotherapy and Rosai-Dorfman disease [2] and database verification using Cryptographic Secure Hash algorithm following Eclipse/Aria version upgrade and database migration [3].

Carbon ions (C+) hadrontherapy is an alternative treatment for radio-resistant tumors. C+ has demonstrated a higher Relative Biological Efficiency (RBE) in vitro and in vivo when compared with photon irradiation (γ -IR). Telomeres located at the end of chromosomes, play different roles in response to C+ and γ-IR. To illustrate the initial telomeric effect, Hamdani et al [1] have studied the telomeric DSBs known as Telomeric damage- Induced Foci (TIF) after C+ and γ-IR which yield the same RBE. They gave C+ irradiation and photon irradiation to U373MG cell line (telomere length 14 kb) and determined TIFs by immunofluorescence analysis of a DSBs signalizing protein 53BP1 (Novus biological: NB100-305) and the telomeric protein TRF1 (Abcam: ab10579) by co-localization counting. Their results are in concordant with the hypothesis that the initial “telomeric effect” results from a pan-ROS prominent effect of γ -IR, while C+ irradiation acts mainly by LMDS. Though initially they have not observed any difference in the number of initial DSBs produced directly at telomeric sites between the two types of irradiation, the percentage of cell with TIF and the average number of TIF per cell increased and reached a peak 6h post-irradiation after γ-IR. Thus, finally they have suggested that residual telomeric damages play a minor role after C+ irradiation and persistent Telomere-Associated DNA damage Foci (TAFs) are predictive of an increased risk of secondary cancer.

Rosai–Dorfman disease (RDD) is an uncommon, often self-limiting benign, not–Langerhans-cell histiocytic proliferative disorder, first described by Rosai and Dorfman in 1969 as sinus histiocytosis with lymphadenopathy. For most instances treatment is not necessary, but some patients with symptomatic condition may require medical intervention. Treatments with acyclovir or interferon alpha have being documented in the literature with anecdotal responses in RTT patients. In the article after brief introduction about RDD author Pellizzon et al [2]., discussed about the Modern RT techniques, such as intensity-modulated radiation therapy (IMRT), which have been introduced to minimize the risk of treatment-related toxicity and stated that there is a paucity of information in the literature describing techniques and doses of radiation therapy (RT), despite its relative success, and probably due to its relationship with potential malignant transformation. At the end he suggested that advances in the planning and delivery of RT in its various modalities warrant the reporting of recent RT treatments.

The Aria EMR and Eclipse TPS use a large database running on a networked server to provide treatment plan information for delivery at the linear accelerators and to record the treatment history and other data. Maintaining the integrity of the database is of the utmost importance to assure accurate and safe treatment after the migration. The incorrect data or the incorrect operation, use, installation, and maintenance of the EMR can have disastrous consequences, potentially delivering fatal doses of radiation in a very short time. In view of this author Baker et al [3]., developed an automatic verification method to make sure that patient data has been correctly migrated. The auto verification method utilizes Eclipse Scripting Application Programming Interface (ESAPI), Cryptographic Hash Algorithm SHA-256 and Microsoft Excel. This method was used as part of our software upgrade and database migration from Varian’s Aria/Eclipse 11 to 13. Finally, they concluded that compared to manual checking process, this process reduces the potential human error associated with tedious one-by-one checking and also allowed for more parameters to be checked at a more detailed level at a fraction of additional labor cost. These scripts can be integrated into Eclipse or can be run as a stand-alone executable program for a more automated process and even more time savings. This approach can also be easily be applied to other Treatment Planning and EMR systems.

For more information:https://jacobspublishers.com/jacobs-journal-of-radiation-oncology-issn-2376-9424/#1529577946543-2a92e81e-6aff

Further, the Journal welcomes articles from all the fields related to Radiation oncology.

References:

  1. Delphine Poncet. Carbon ions Versus γ-Irradiation: The Telomeric Effect in Cancer Cells. J J Rad Oncol. 2016, 3(3): 031.
  2. Antonio Cássio Assis Pellizzon. Radiotherapy and Rosai-Dorfman Disease. J J Rad Oncol. 2016, 3(3): 032.
  3. Zhigang Xu. Database Verification Using Cryptographic Secure Hash Algorithm following Eclipse/Aria Version Upgrade and Database Migration. J J Rad Oncol. 2016, 3(3): 033.

 

 

 

Be the first to comment on "Radiation Oncology"

Leave a comment

Your email address will not be published.


*